Additionally, M2-like TAMs activated using CD40 agonists can reportedly reacquire antigen-presenting capabilities and become tumoricidal, resulting in the reestablishment of tumor immune surveillance and the short-term reduction of tumor volume (150). The gene discussed is CD40; the disease is neoplasm.